|
|
Blood, 15 February 2006, Vol. 107, No. 4, pp. 1276-1283.
Prepublished online as a Blood First Edition Paper on October 4, 2005; DOI 10.1182/blood-2005-02-0819.
 Previous Article | Table of Contents | Next Article 
HOW I TREAT
How I treat refractory CLL
Emili Montserrat,
Carol Moreno,
Jordi Esteve,
Alvaro Urbano-Ispizua,
Eva Giné, and
Francesc Bosch
From the Institute of Hematology and Oncology, Department of Hematology, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Hospital Clínic, University of Barcelona, Barcelona, Spain.
Therapy for patients with chronic lymphocytic leukemia (CLL) has greatly changed over the past few years. After years of stagnation, with treatment revolving around the use of rather ineffective drugs such as alkylators, many patients are now being treated with more effective agents such as purine analogs either alone or combined with other drugs and/or monoclonal antibodies. Treatment of patients refractory to these treatments is particularly challenging and should be decided only upon a careful evaluation of the disease, patient characteristics, and prognostic factors. Refractory disease should be clearly separated from relapsing disease. The only curative therapy for patients with CLL, including those with refractory disease, is allogeneic stem cell transplantation. However, the use of allogeneic transplantation is limited because of the advanced age of most patients and the high transplant-related mortality (TRM). Transplants with nonmyeloablative regimens may reduce TRM and allow more patients to receive transplants more safely. For patients in whom an allogeneic transplantation is not feasible or in whom it is deemed inappropriate, participation in phase 2 trials should be encouraged. Finally, to investigate mechanisms to overcome resistance to therapy in CLL and to identify patients that might gain benefit from early, intensive therapies (eg, based on biologic markers) constitute a challenge that needs active investigation.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. Buchner, S. Fuchs, G. Prinz, D. Pfeifer, K. Bartholome, M. Burger, N. Chevalier, L. Vallat, J. Timmer, J. G. Gribben, et al.
Spleen Tyrosine Kinase Is Overexpressed and Represents a Potential Therapeutic Target in Chronic Lymphocytic Leukemia
Cancer Res.,
July 1, 2009;
69(13):
5424 - 5432.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Rossi, M. Cerri, C. Deambrogi, E. Sozzi, S. Cresta, S. Rasi, L. De Paoli, V. Spina, V. Gattei, D. Capello, et al.
The Prognostic Value of TP53 Mutations in Chronic Lymphocytic Leukemia Is Independent of Del17p13: Implications for Overall Survival and Chemorefractoriness
Clin. Cancer Res.,
February 1, 2009;
15(3):
995 - 1004.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Lopez-Guerra, L. Trigueros-Motos, M. Molina-Arcas, N. Villamor, F. J. Casado, E. Montserrat, E. Campo, D. Colomer, and M. Pastor-Anglada
Identification of TIGAR in the equilibrative nucleoside transporter 2-mediated response to fludarabine in chronic lymphocytic leukemia cells
Haematologica,
December 1, 2008;
93(12):
1843 - 1851.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. C. Kluin-Nelemans, J. L. Coenen, J. E. Boers, G. W. van Imhoff, and S. Rosati
EBV-positive immunodeficiency lymphoma after alemtuzumab-CHOP therapy for peripheral T-cell lymphoma
Blood,
August 15, 2008;
112(4):
1039 - 1041.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-J. Lee, K. A. Foon, R. B. Mailliard, R. Muthuswamy, and P. Kalinski
Type 1-polarized dendritic cells loaded with autologous tumor are a potent immunogen against chronic lymphocytic leukemia
J. Leukoc. Biol.,
July 1, 2008;
84(1):
319 - 325.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Gine, M. Crespo, A. Muntanola, E. Calpe, M. J. Baptista, N. Villamor, E. Montserrat, and F. Bosch
Induction of histone H1.2 cytosolic release in chronic lymphocytic leukemia cells after genotoxic and non-genotoxic treatment
Haematologica,
January 1, 2008;
93(1):
75 - 82.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
